The criteria for successful application of adjuvant chemotherapy are: a poor prognosis for cure with primary surgical therapy alone, and evidence that the proposed adjuvant therapy is more effective when used than when withheld. In nonseminomatous testicular tumors, both of these points are at least open to question. Our data suggest that adjuvant chemotherapy is not necessary at all in patients with stage I disease and that it confers no survival advantage for patients with stage II disease. In fact, those patients with stage II disease who receive single drug (actinomycin D) adjuvant therapy appear to fare less well than those who are treated expectantly following node dissection, and who are subsequently treated with combination chemotherapy only at the time of clinical relapse.
|Original language||English (US)|
|Number of pages||10|
|Journal||Urologic Clinics of North America|
|State||Published - Dec 1 1980|
ASJC Scopus subject areas